## PATENT COOPERATION TREATY

TRANSLATION From the INTERNATIONAL SEARCHING AUTHORITY WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) Applicant's or agent's file reference FOR FURTHER ACTION 09732 See paragraph 2 below International application No. International filing date (day/month/year) Priority date (day/month/year) PCT/JP2005/003437 23.02.2005 23.02.2004 International Patent Classification (IPC) or both national classification and IPC Applicant Dainippon Sumitomo Pharma Co., Ltd. This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Name and mailing address of the ISA/JP Authorized officer Facsimile No. Telephone No.

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/JP2005/003437

Bo	x No. I Basis of this opinion								
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.								
	This opinion has been established on the basis of a translation from the original language into the following language								
	, which is the language of a translation furnished for the purposes of international search (under								
	Rule 12.3 and 23.1(b)).								
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:								
	a. type of material								
	a sequence listing								
	table(s) related to the sequence listing								
	b. format of material								
	in written format								
	in computer readable form								
	c. time of filing/furnishing								
	contained in the international application as filed.								
	filed together with the international application in computer readable form.								
	furnished subsequently to this Authority for the purposes of search.								
,	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or								
3.	furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.								
4.	Additional comments:								
ŀ									
	· · · · · · · · · · · · · · · · · · ·								

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/JP2005/003437

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability									
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:									
	the entire international application								
$\boxtimes$	claims Nos. 12								
because:									
$\boxtimes$	the said international application, or the relate to the following subject matter of	ne said claims Nos. 12 which does not require an international preliminary examinatio	n ( <i>specify</i> ):						
	Claim 12 is an invention of a commercial method and an advertising method, namely a method of business activity, which does not require an international preliminary examination in accordance with PCT Rule 67.1 (iii).								
	•		•						
	the description, claims or drawings (indicate particular elements below) or said claims Nos.  are so unclear that no meaningful opinion could be formed (specify):								
П									
	the claims, or said claims Nos.  by the description that no meaningful	opinion could be formed.	are so inadequately supported .						
$\boxtimes$	no international search report has been	n established for said claims Nos. 12	, character and the contract						
	the nucleotide and/or amino acid sequ Instructions in that:	nence listing does not comply with the standard provided for it	n Annex C of the Administrative						
	the written form	has not been furnished							
		does not comply with the standard							
	the computer readable form	has not been furnished							
		does not comply with the standard							
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply w technical requirements provided for in Annex C-bis of the Administrative Instructions.								
	See Supplemental Box for further deta	ails.							

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/JP2005/003437

Claims	Sox No. V Reasoned stateme citations and expl	nt under Ri anations su	ule 43bis.1(a)(i) wit pporting such state	h regard to novel ment	ty, inventive step	or industrial appli	cability;
Industrial applicability (IA)  Claims  Industrial applicability (IA)  Claims  Claims  Claims  Claims  Claims  Claims  1-11  Claims  Cl	. Statement						
Industrial applicability (IA)  Claims  Industrial applicability (IA)  Claims  1-11  Claims  1-11  Claims  Claims  1-11  Claims  Claims  1-11  Claims  Claims  Claims  1-11  Claims  Claims  1-11  Claims  Claims  Claims  1-11  Claims  Claims  Claims  1-11  Claims  Claims  Claims  1-11  Claims  Claims  Claims  Claims  Claims  Claims  1-11  Claims  Clai	Novelty (N)	Claims	1-11		···		YES
Industrial applicability (IA)  Claims  1-11  Claims  1-11  Claims  1-11, detecting D-dimmer and H-FABP in the blood, a thereby discriminating Stanford type A acute aortic dissection and Stanford type B acute ao dissection from acute myocardial infarction is not described in any of the documents cited in the Is nor is obvious to a person skilled in the art.		Claims					NO NO
In the inventions described in claims 1-11, detecting D-dimmer and H-FABP in the blood, a thereby discriminating Stanford type A acute aortic dissection and Stanford type B acute ao dissection from acute myocardial infarction is not described in any of the documents cited in the Is nor is obvious to a person skilled in the art.	Inventive step (IS)	Claims	1-11				YES
Citations and explanations:  In the inventions described in claims 1-11, detecting D-dimmer and H-FABP in the blood, a thereby discriminating Stanford type A acute aortic dissection and Stanford type B acute aordissection from acute myocardial infarction is not described in any of the documents cited in the Is nor is obvious to a person skilled in the art.							
Citations and explanations:  In the inventions described in claims 1-11, detecting D-dimmer and H-FABP in the blood, a thereby discriminating Stanford type A acute aortic dissection and Stanford type B acute aordissection from acute myocardial infarction is not described in any of the documents cited in the Is nor is obvious to a person skilled in the art.	Industrial applicability (IA)	Claims	1-11				YES
In the inventions described in claims 1-11, detecting D-dimmer and H-FABP in the blood, a thereby discriminating Stanford type A acute aortic dissection and Stanford type B acute ao dissection from acute myocardial infarction is not described in any of the documents cited in the Isnor is obvious to a person skilled in the art.							
In the inventions described in claims 1-11, detecting D-dimmer and H-FABP in the blood, a thereby discriminating Stanford type A acute aortic dissection and Stanford type B acute ao dissection from acute myocardial infarction is not described in any of the documents cited in the Isnor is obvious to a person skilled in the art.	Citations and explanations:						<u> </u>
	dissection from acute m	yocardia	l infarction is r	ot described	in any of the o	locuments cite	d in the ISF
			•				
					-		